Projects

Code

PI22/00374

Leader

Josep Maria Haro Abad

Rol

Individual

Starting date

2023

End date

2025

Import total

82280€

Objectius

El objetivo de este estudio es evaluar el impacto de la pandemia de COVID-19 en la salud física y mental y el bienestar utilizando una cohorte representativa de la población que se evaluó antes y durante la pandemia de COVID-19 y que se evaluará después de la pandemia. Este proyecto se centra en los trastornos mentales y el suicidio, pero la cohorte se puede utilizar para otros fines científicos. Los participantes corresponden a la muestra de refresco del proyecto "Edad con Salud": www.edadconsalud.com (PI16/00218, PI16/01073, PI19/00235 y PI19/00088) que incluye a 3.000 personas que viven en la provincia de Barcelona y la Comunidad Autónoma de Madrid. La primera ola de recopilación de datos comenzó en 2019, antes de la pandemia. La segunda evaluación se realizó telefónicamente tras finalizar el estricto confinamiento en 2020. La recolección de datos en esta tercera ola se realizará de manera presencial mediante entrevistas personales asistidas por computadora (CAPI) con preguntas sobre características sociodemográficas, historial laboral, estado de salud y funcionamiento/discapacidad, factores de riesgo y conductas de vida saludables, enfermedades crónicas, trastornos mentales, soledad y características del entorno social, bienestar y exposición al ruido y espacios verdes, entre otros. Además, los participantes se someterán a medidas antropométricas: peso, talla y perímetro de cintura y pruebas de rendimiento: presión arterial, pulso, velocidad de la marcha, visión, fuerza de prensión, pruebas cognitivas.

Code

PMP22/00008

Leader

Rafael Artuch Iriberri

Rol

Coordinador

Starting date

2023

End date

2025

Import total

4719000€

Objectius

The ultimate goal of Pediatric Precision Medicine is to stratify children affected by diseases to improve diagnosis and medical treatments. Translational investigators are bringing to bear ever greater amounts of heterogeneous clinical
data and scientific information to create classification strategies that enable the matching of intervention to underlying mechanisms of disease in subgroups of patients. Most pediatric genetic diseases such as neurodevelopmental
disorders, inherited metabolic diseases, neuromuscular disorders, epilepsies and other ultra-rare monogenic conditions are important causes of infantile death and disability in Spain and worldwide.
The main objectives of this project are the 1- Establishment of a Pediatric Research Network on Rare Diseases for Precision Medicine in Spain; 2- Application of Electronic Medical Record standards by mean of the introduction of a
“minimum clinical data set” in four disease groups in order to obtain a set of common standards for clinical data that we are planning to include in the ERNs, CSUR and CIBERs; 3- Implementation of common tools among pediatric units and
the deployment of “Use Cases” for IMPaCT-Data and IMPaCT-Genomics. 4- Application of automated tools for analyzing and sharing the genomic information of children with rare diseases and the interaction with IMPaCT -
Genomics.
The project will deploy a federated data platform following the guidelines, documentation and demonstrators developed by IMPaCT-Data. This pilot project is intended to give the initial kick-off of the Network, to structure its minimum bases
taking advantage of existing phenotypic and genomic data in 300 patients and carry out genomic studies and structured phenotypic analysis as a pilot study in 200 further patients with four groups of pathologies. Once the
Network is established, funding both in clinical care aswell as research at a Regional, National, European and International levels will be applied for.

Code

FI22/00160

Leader

Angel Montero Carcaboso

Rol

Individual

Starting date

2023

End date

2025

Import total

89900€

Objectius

ISCIII_Angel Montero

Code

CP22/00029

Leader

Ignacio Aznar Lou

Rol

Individual

Starting date

2023

End date

2026

Import total

268600€

Objectius

ISCIII_Ignacio Aznar

Code

CP22/00029 (Proyecto)

Leader

Ignacio Aznar Lou

Rol

Individual

Starting date

2023

End date

2026

Import total

40000€

Objectius

ISCIII_Ignacio Aznar

Code

101057655

Leader

Raffaele Fiorillo

Rol

Participant

Starting date

2022

End date

2026

Import total

354125€

Objectius

Health services are increasingly moving towards a treatment continuum aligned with the patient journey. This transition will critically depend on the successful deployment of trustworthy AI-enhanced technologies that are accurate, secure, and trusted. The AISN project will develop and validate operating procedures and guidelines for integrating AI in a healthcare continuum, focussing on
post-stroke rehabilitation. AISN delivers a representative AI health platform built from integrating validated platforms for data acquisition and access, clinical interpretation, whole-brain simulation, clinically validated intervention delivery and optimization and model-based prediction. The AISN integrated platform will be validated in the clinical context of rehabilitation in the outpatient and
at-home phase and facilitate a concrete assessment of the fundamental ways in which AI-enhanced clinical decision-support will change the care pathway and the formulation of novel AI compatible treatment guidelines. AISN ensures an ethical approach by developing legal and ethical guidelines for the robust, fair, and trustworthy deployment of AI in health and validating acceptance and
transparency of its solutions. Building on the AISN platform, the project will test current standard operating procedures for integrating AI in health care and formulate and validate new ones where needed. The AISN guidelines and procedures will emphasize the evidence base and safety of clinical interventions, transparency, prognostics at varying time-scales, personalization of
interventions, access to disease-specific information by clinicians, patients and their carers, and assure that the potential of AI is fully developed in the service of value-based medicine satisfying standards of security and safety. We will go beyond currently available guidelines and frameworks by emphasizing explainability, AI tools with evolving performance, and the dynamic interaction between users and algorithms.

Code

FPU2021-02218

Leader

Susana Ochoa Güerre

Rol

Individual

Starting date

2022

End date

2026

Import total

93228.29€

Objectius

MINISTERIO DE UNIVERSIDADES_Susana Ochoa

Code

PMP21/00075

Leader

Cinzia Emilia Lavarino

Rol

Participant

Starting date

2022

End date

2025

Import total

220000€

Objectius

ISCIII_Dra. Cinzia Lavarino

Code

ICI21/00033

Leader

Susana Rives Solà

Rol

Coordinador

Starting date

2022

End date

2025

Import total

1705884.4€

Objectius

ISCIII_Susana Rives

Code

PI21/01268

Leader

Alexis Arzimanoglou

Rol

Individual

Starting date

2022

End date

2024

Import total

93170€

Objectius

Recent evidence has shown a higher risk of presenting cognitive and emotional disorders in chronic epilepsy, but those are often underdiagnosed and little is known about their biological basis. Numerous studies have demonstrated brain connectivity alterations in epilepsy patients and their relation to neurobehavioral comorbidities.
However, the majority comprised small samples of patients with a long-standing epilepsy, which does not exclude an impact of the chronicity of epilepsy over the results. The present project aims to prospectively and longitudinally investigate the degree to which structural and functional connectivity impairments are associated with
neurobehavioral disorders in different types of new-onset childhood epilepsies, thus serving as biomarkers for the early detection of these disorders and enabling early personalization of epilepsy care.
Following a pilot study to demonstrate the feasibility of our project, we will increase the sample size to 130 patients aged 6-16yrs, with new-onset epilepsy divided in focal structural, focal idiopathic and generalized idiopathic (ILAE 2017). They will undergo neuropsychological evaluations and MRI acquisitions at time of recruitment and 18 months later. Neuroimaging will consist of T1/T2-weighted, FLAIR, DTI and rs-fMRI sequences (no sedation). After their processing and analysis, neuroimaging findings will be correlated with neurobehavioral scores at both timepoints, with the aim of evaluating to which extent they are able to predict cognitive and emotional impairment.
The same procedures will be performed on a control group comprised of healthy subjects obtained from NIH database matched by age to contrast children with newly diagnosed epilepsy and neurotypical development.